Public Release: 

Open-access journals Neoplasia and Translational Oncology now published by Elsevier

Elsevier has acquired Neoplasia Press Inc.


New York, January 6, 2015 - Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, has announced that it has acquired Neoplasia Press Inc. and assumes publication of its flagship journals, Neoplasia and Translational Oncology. These peer-reviewed, open access journals are now published by Elsevier under the Neoplasia Press imprint.

"We are delighted to add these highly regarded, rapid publication journals to our oncology journal portfolio and to our growing list of open access journals serving the global biomedical community," commented Anne Kitson, Executive Vice President, Health and Medical Sciences Journals at Elsevier. "We look forward to working closely with the Editors-in-Chief and editorial teams to ensure the journals' continuing success and expand their already impressive communities of contributors and readers."

With a significant Impact Factor of 5.398* Neoplasia is a well-established cancer research journal that publishes the results of novel investigations in all areas of oncology research. Under the editorial leadership of Alnawaz Rehemtulla, PhD, Ruth Tuttle Freeman Research Professor and Director of the Molecular Imaging Division, Department of Radiation Oncology, University of Michigan, the journal's breadth encompasses not only the traditional disciplines of cancer research, but also emerging fields and interdisciplinary investigations. Published monthly, Neoplasia features studies describing new molecular and genetic findings relating to the neoplastic phenotype and laboratory and clinical studies demonstrating creative applications of advances in the basic sciences to risk assessment, prognostic indications, detection, diagnosis, and treatment.

Sister publication Translational Oncology was successfully launched in 2008 and publishes the results of novel research investigations that bridge the laboratory and clinical settings, including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis, and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Guided by Editor-in-Chief Theodore S. Lawrence, MD, PhD, Isadore Lampe Professor and Department Chair, Department of Radiation Oncology, University of Michigan, with a 2.558 Impact Factor*, this bimonthly journal publishes laboratory studies of novel therapeutic interventions as well as clinical trials that evaluate new treatment paradigms for cancer.

"The transition to Elsevier has been extremely smooth," remarked Neoplasia Press Inc. Founding Editor Brian D. Ross, PhD, Robert A. Berg MD Radiology Research Professor, University of Michigan Medical School and Prof. Rehemtulla. "We are confident that Elsevier will continue to support the journals' underlying mission of serving both the scientific and clinical communities by openly disseminating important data and ideas in cancer research to facilitate the progress of research and ultimately provide those fighting neoplastic diseases with new diagnostic, preventative, and therapeutic options."

Neoplasia and Translational Oncology are available on their own dedicated Elsevier sites as well as via ScienceDirect, Elsevier's full-text platform for the library community. Both journals are included in PubMed and PubMed Central, increasing the discoverability of their content by researchers, clinicians and other healthcare professionals worldwide.


*2013 Journal Citation Reports, published by Thomson Reuters, 2014.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey -- and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.